Intersect ENT (XENT) Getting Somewhat Favorable News Coverage, Report Finds

News stories about Intersect ENT (NASDAQ:XENT) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intersect ENT earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.7122482192548 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

XENT has been the subject of a number of recent research reports. Bank of America Corporation raised their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Zacks Investment Research lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Canaccord Genuity raised their price target on shares of Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. BidaskClub lowered shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Intersect ENT currently has an average rating of “Buy” and a consensus target price of $30.88.

Shares of Intersect ENT (NASDAQ:XENT) traded down $0.35 during midday trading on Friday, hitting $28.55. 149,699 shares of the stock were exchanged, compared to its average volume of 232,983. Intersect ENT has a twelve month low of $9.20 and a twelve month high of $33.25.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The business had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The business’s revenue was up 20.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.22) EPS. research analysts forecast that Intersect ENT will post -0.63 earnings per share for the current fiscal year.

In related news, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction on Monday, November 6th. The shares were sold at an average price of $27.78, for a total value of $356,500.74. Following the sale, the chief financial officer now owns 27,833 shares of the company’s stock, valued at approximately $773,200.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Richard E. Kaufman sold 22,425 shares of Intersect ENT stock in a transaction on Monday, August 28th. The shares were sold at an average price of $30.22, for a total transaction of $677,683.50. Following the completion of the sale, the chief operating officer now directly owns 149,821 shares in the company, valued at approximately $4,527,590.62. The disclosure for this sale can be found here. Insiders sold a total of 115,363 shares of company stock worth $3,406,647 in the last three months. 13.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/18/intersect-ent-xent-getting-somewhat-favorable-news-coverage-report-finds.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply